Physician profile
John K Cherian
NPI 1164699435
$7,245.39
in general payments reported to CMS, 2019-2025
35 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2020: $863 · 2021: $1,105 · 2022: $1,030 · 2023: $1,167 · 2024: $998 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,956 · Education: $32.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,955.65 |
| Education | $32.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $846.29 | 2019-2024 | Xarelto |
| Pfizer INC. | $782.49 | 2019-2025 | |
| Amgen INC. | $779.16 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $577.09 | 2019-2024 | Mitraclip, Gallant |
| Novartis Pharmaceuticals Corporation | $491.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $454.03 | 2019-2024 | Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.91 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $402.35 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $354.06 | 2019-2025 | Watchman Flx, Varithena Administration Pack |
| E.R. Squibb & Sons, L.L.C. | $311.80 | 2019-2025 | Camzyos, Eliquis |
| Atricure, INC. | $216.26 | 2022-2023 | |
| Novo Nordisk INC | $203.02 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $158.43 | 2019-2024 | Opsumit |
| Scpharmaceuticals INC. | $154.19 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $144.23 | 2021-2025 | Amvuttra, Onpattro |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.99 | 2019-2021 | |
| Esperion Therapeutics, INC. | $130.73 | 2020-2025 | Nexletol |
| Edwards Lifesciences Corporation | $83.73 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Angiodynamics, INC. | $83.45 | 2021 | |
| Amarin Pharma, INC. | $59.83 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $54.84 | 2023 | Edarbi |
| Astellas Pharma US INC | $52.35 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.19 | 2023 | |
| Abiomed | $49.02 | 2024-2025 | Impella |
| Inspire Medical Systems, INC. | $42.34 | 2023-2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $38.83 | 2021 | |
| Medtronic, INC. | $33.26 | 2021-2024 | Reveal Linq |
| Bridgebio Pharma, INC. | $26.63 | 2025 | Attruby |
| Cvrx, INC. | $22.61 | 2024 | Barostim Neo System |
| Irhythm Technologies, INC. | $21.25 | 2023 | Zio Xt Patch |
| Lantheus Medical Imaging, INC. | $19.24 | 2023 | Definity |
| Phadia US INC. | $16.81 | 2022 | |
| Cardiva Medical, INC. | $16.71 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.29 | 2022 | |
| Kestra Medical Technology Services, INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.